Does Amerigroup Cover Novolog?

How Amerigroup Formulary Coverage Works for Insulin

Amerigroup is a managed care organization owned by Elevance Health (formerly Anthem) that administers Medicaid, Medicare Advantage, and marketplace plans across more than 20 states. Each state contract produces a distinct formulary. That means Novolog might sit on Tier 2 (preferred brand) in Georgia but land on Tier 3 (non-preferred brand) in Texas.

Formulary tiers matter because they determine your out-of-pocket cost and whether you need prior authorization. The Centers for Medicare & Medicaid Services (CMS) requires all Medicaid managed care plans to cover at least one drug in every therapeutic class, and rapid-acting insulin analogs are a protected class under most state Medicaid programs. A 2023 analysis published in Diabetes Care found that 94% of state Medicaid programs covered at least one rapid-acting insulin analog without prior authorization [1]. Amerigroup follows its state contract rules, so your specific plan document is the final word.

For Medicaid enrollees, federal law caps insulin copays at nominal amounts. The Inflation Reduction Act of 2022 capped insulin copays at $35 per month for Medicare Part D beneficiaries, and many state Medicaid programs already set copays at $0 to $3 for preferred drugs [2]. Amerigroup Medicaid members in most states pay $0 for preferred-tier insulins and $1 to $4 for non-preferred brands.

Novolog Formulary Tier by Plan Type

The tier Novolog occupies on your Amerigroup plan shapes everything from copay to pharmacy workflow. Here is what to expect across the three main plan categories.

Amerigroup Medicaid plans typically list one rapid-acting insulin as preferred. In states where Novo Nordisk holds the supplemental rebate contract, Novolog is preferred. In states where Eli Lilly holds it, Humalog (insulin lispro) takes the preferred slot and Novolog requires prior authorization. A 2022 survey in JAMA Internal Medicine found that Medicaid managed care formularies changed preferred insulin brands an average of every 18 months based on rebate negotiations [3].

Amerigroup Medicare Advantage (Dual-eligible/DSNP) plans must follow the CMS Part D formulary framework. Under the Inflation Reduction Act, all covered insulin products carry a maximum $35 monthly copay at the pharmacy regardless of tier [2]. Novolog appears on most Amerigroup DSNP formularies, though it may require using a preferred pharmacy.

Amerigroup marketplace (ACA) plans, available in select states, follow standard commercial formulary design. Novolog typically sits on Tier 3 (non-preferred brand) with copays ranging from $30 to $75 before any manufacturer coupon. The Novo Nordisk copay savings card can reduce the cost to as low as $25 per prescription for commercially insured patients [4].

Prior Authorization and Step Therapy Requirements

Prior authorization is Amerigroup's way of confirming medical necessity before covering a non-preferred drug. If Novolog is non-preferred on your plan, your prescriber will need to document why the preferred alternative is not appropriate.

Common clinical reasons that satisfy Amerigroup prior authorization criteria include a documented allergy or adverse reaction to the preferred insulin, therapeutic failure after a minimum 30-day trial of the preferred agent, or a clinical contraindication supported by lab work. The American Diabetes Association's Standards of Care 2024 states that insulin regimens should be individualized, and formulary restrictions should not delay access to needed therapy [5].

Step therapy is related but distinct. It requires you to try (and fail on) the preferred drug before the plan will cover the non-preferred option. A 2021 study in Annals of Internal Medicine examined step therapy for insulin analogs in Medicaid populations and found that mandatory switching between rapid-acting insulin analogs increased hypoglycemic events by 12% in the first 90 days after the switch [6]. This finding gives prescribers strong grounds to request a step therapy override when a patient is already stable on Novolog.

The turnaround time for Amerigroup prior authorization decisions is typically 24 to 72 hours for standard requests and 24 hours for urgent requests, consistent with CMS and state regulatory timelines.

Novolog vs. Its Authorized Generic: Which Does Amerigroup Prefer?

Novo Nordisk launched an authorized generic version of Novolog (labeled simply as "insulin aspart injection") in 2020 at a list price roughly 50% lower than brand Novolog [4]. This authorized generic is the exact same formulation manufactured on the same production line. The difference is the label and the price.

Many Amerigroup formularies now list the authorized generic insulin aspart as preferred over brand-name Novolog. When this is the case, your pharmacy can automatically dispense the generic unless your prescriber writes "brand medically necessary" on the prescription. A 2023 report from the FDA Office of Generic Drugs confirmed that authorized generic insulins are rated as therapeutically equivalent (AB-rated) to their reference products, meaning there is no clinical difference in safety or efficacy [7].

If your Amerigroup plan covers the authorized generic at Tier 1, switching from brand Novolog can eliminate your copay entirely under Medicaid or reduce it by $10 to $30 under a marketplace plan. Ask your pharmacist whether generic insulin aspart is available at your pharmacy before assuming you must pay the brand-name price.

How to Check Your Specific Amerigroup Formulary

Formularies change at least annually, and mid-year updates occur when rebate contracts shift. Do not rely on general guidance alone. Here are three concrete steps to confirm your coverage.

Step 1: Log into the Amerigroup member portal. Manage to the "Find a Drug" or "Formulary Search" tool. Enter "Novolog" or "insulin aspart" and select your plan year. The tool will display the tier, prior authorization status, quantity limits, and preferred alternatives.

Step 2: Call Amerigroup member services. The number is on the back of your insurance card. Ask specifically: "Is Novolog on my formulary, and does it require prior authorization or step therapy?" Request the agent's name and a reference number for your records.

Step 3: Ask your pharmacy to run a test claim. Your pharmacist can submit a test adjudication to Amerigroup's system and see the exact copay and any rejection codes in real time. This takes under two minutes.

The National Association of Boards of Pharmacy recommends verifying coverage at the pharmacy level before each refill, because formulary status can change after annual plan renewals [8].

What to Do If Amerigroup Denies Novolog Coverage

A denial is not the end of the road. Several pathways exist to secure coverage or reduce your cost.

File a formulary exception. Your prescriber submits a letter explaining why Novolog is medically necessary for you. The letter should reference your A1C history, any adverse reactions to alternative insulins, and relevant guidelines from the ADA Standards of Care [5]. Amerigroup must respond within 72 hours for standard exceptions and 24 hours for expedited requests.

Appeal the denial. If the exception is denied, you have the right to a formal appeal. Medicaid members also have the right to a state fair hearing, an independent review process administered by the state Medicaid agency. A 2020 analysis in Health Affairs found that 40% to 60% of insulin prior authorization denials were overturned on first appeal [9].

Use Novo Nordisk's Patient Assistance Program (PAP). Uninsured patients or those facing financial hardship can apply for free Novolog through Novo Nordisk's PAP. Eligibility generally requires household income below 400% of the federal poverty level [4].

Consider the $35 insulin cap. If you are on a Medicare Advantage DSNP plan through Amerigroup, the Inflation Reduction Act guarantees your Novolog copay will not exceed $35 per 30-day supply, regardless of formulary tier [2]. Some states have passed similar caps for commercial and Medicaid plans.

The Cost of Novolog Without Insurance vs. With Amerigroup

Understanding the price difference helps you see exactly what Amerigroup coverage saves you. Brand Novolog carries a wholesale acquisition cost (WAC) of approximately $289 per 10 mL vial and $573 for a box of five 3 mL FlexPens [4]. The authorized generic lists at roughly $145 per vial.

With Amerigroup Medicaid, your cost for a preferred-tier insulin is typically $0 to $3. Even if Novolog sits on a non-preferred tier, Medicaid copays are federally capped at $4 for brand-name drugs for most beneficiaries with income below 150% of the federal poverty level [10]. The savings over cash price exceeds $280 per vial.

A 2024 JAMA Network Open study found that among Medicaid managed care enrollees with type 1 diabetes, mean annual out-of-pocket spending on insulin was $47, compared with $1,212 for commercially insured patients and $3,490 for uninsured individuals filling the same prescriptions [11].

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "No person with diabetes should ever ration insulin due to cost. The tools exist, from manufacturer programs to federal caps, to make insulin affordable for everyone" [5].

Novolog Alternatives Covered by Amerigroup

If Novolog is non-preferred or you want to explore lower-cost options, several rapid-acting insulin alternatives may be available on your Amerigroup formulary.

Humalog (insulin lispro) is the most common preferred alternative. A Cochrane systematic review of 10 randomized trials (N=2,751) found no clinically significant difference in A1C reduction or hypoglycemia rates between insulin aspart and insulin lispro in adults with type 1 or type 2 diabetes [12]. Switching between these two analogs is generally straightforward on a unit-for-unit basis.

Admelog (insulin lispro, Sanofi) is a follow-on biologic to Humalog that some Amerigroup plans list at a lower tier. The FDA approved Admelog in 2017 based on the SORELLA trials, which demonstrated bioequivalence to Humalog [7].

Lyumjev (insulin lispro-aabc) is an ultra-rapid formulation that begins working approximately 3 minutes faster than standard lispro. The PRONTO-T1D trial (N=1,222) showed that Lyumjev reduced 1-hour postprandial glucose by 12.0 mg/dL more than Humalog (P<0.001) [13]. Some Amerigroup plans cover Lyumjev, though it often requires prior authorization.

ReliOn insulin (Walmart) is an over-the-counter option that does not require a prescription or insurance. ReliOn Novolin R is regular human insulin (not a rapid-acting analog) and costs approximately $25 per vial. It has a slower onset and longer duration than Novolog, which makes mealtime dosing less flexible. The ADA does not recommend switching from analog to human insulin without clinician supervision due to differences in pharmacokinetics and hypoglycemia risk [5].

Tips for Reducing Your Novolog Cost With Amerigroup

Even with coverage, small strategies can cut your out-of-pocket spending further.

Use a preferred pharmacy. Amerigroup contracts with specific pharmacy networks, and using an out-of-network pharmacy can double your copay or result in a claim denial. Most Amerigroup Medicaid plans include CVS, Walgreens, Walmart, and independent pharmacies in their network, but verify yours.

Request 90-day fills. If your plan allows it, filling a 90-day supply at a mail-order pharmacy reduces trips and may lower per-unit cost. A 2021 study in the American Journal of Managed Care found that 90-day insulin fills improved adherence by 15% compared with 30-day fills [14].

Ask about vials vs. pens. A 10 mL Novolog vial contains 1,000 units and costs less per unit than FlexPens. If you are comfortable using syringes, vials can save $50 to $100 per month at commercial copay tiers. For Medicaid members where copays are already minimal, the savings are smaller but the principle holds.

Stack manufacturer support. For commercially insured Amerigroup members, the Novo Nordisk copay savings card reduces Novolog copays to as low as $25 per fill for up to 24 months [4]. This card does not apply to government-funded plans (Medicaid, Medicare, TRICARE), but commercially insured members should always check eligibility.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "The biggest barrier to insulin access is not the list price. It is the complexity of navigating formularies, prior authorizations, and copay structures that patients face at the pharmacy counter" [5].